The purpose of this study is to investigate if daily consumption of barley beta-glucans impact on lipid and glucose metabolism and on intestinal microbiota in a population with metabolic syndrome. It is assumed that two month intervention with beta-glucans will improve some clinical signs of metabolic syndrome and alter composition of intestinal microbiota. Variation in microbiota composition will be investigated with emphasis on Bacteroidetes and Firmicutes ratio. Furthermore it is presupposed that consumption of beta-glucans will stimulate growth of beneficial intestinal bacteria from genus Lactobacillus and Bifidobacteria and consequently effect production of short chain fatty acids in population with metabolic syndrome. Moreover it is presupposed that two-month consumption of beta-glucans will have influence on glucose metabolism and will consequently improve insulin resistance within people with metabolic syndrome. It is assumed that two-month consumption of beta-glucans will improve specific plasma lipid content in population with metabolic syndrome.